Rifaximin in the treatment of Crohn´s disease. Results of the GRACE 02 study
Dana Ďuricová Orcid.org 1, Martin Bortlík Orcid.org 1,2,3, Milan Lukáš Orcid.org 1
+ Affiliation
Summary
Summary
It has been shown that the intestinal microbial system plays an important role in the induction and maintenance of intestinal inflammation in patients with Crohn´s disease. Long-term antimicrobial therapy in patients with Crohn´s disease is a part of therapeutical armamentarium mainly for septic or perianal complications. The GRACE 02 study was done to assess the rifaximin bioavailability, safety and efficacy in patients with mild to moderate ileal or colonicluminal Crohn´s disease. Rifaximin in the form of gastro-resistant granules was applied in two dosage regimens (800 mg vs. 1 600 mg daily). The study was performed atone centre and 24 patients were recruited. The results of the study proved that both dosage regimens of rifaximin gastro-resistant granules were well tolerated, safe, and had extremely low bio-availability. The clinical efficacy in terms of remission and response rates was higher in those who were treated with a higher dose of rifaximin compared to the lower dosage regimen (58 % vs. 33 %).
Keywords
Crohn’s disease, inflammatory bowel disease, rifaximin, rifaximin, ulcerative colitisTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users